First reported study of daily, high dose transdermal application of oxybutynin in a humid country
Objectives:: We investigated the efficacy and safety of a transdermal oxybutynin patch in treating patients with overactive bladder (OAB). Methods:: Ninety-three adult patients with OAB who were under stable treatment with antimuscarinic agents, mirabegron, or both for at least 1 month were prospect...
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Elsevier
2022-12-01
|
| Sarja: | Continence |
| Aiheet: | |
| Linkit: | http://www.sciencedirect.com/science/article/pii/S2772973722009948 |